Skip to main content
Top
Published in: Advances in Therapy 11/2021

Open Access 01-11-2021 | Heart Failure | Original Research

Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia

Authors: Rubeen Israni, Keith A. Betts, Fan Mu, Jill Davis, Jessie Wang, Deborah Anzalone, Gabriel I. Uwaifo, Harold Szerlip, Vivian Fonseca, Eric Wu

Published in: Advances in Therapy | Issue 11/2021

Login to get access

Abstract

Introduction

The progression of mild hyperkalemia and the predictors of progression have not been well characterized. In this study we aimed to characterize the progression of hyperkalemia and identify the risk factors for hyperkalemia progression.

Methods

Adults with mild hyperkalemia (at least one serum potassium measure > 5.0 and ≤ 5.5 mEq/L) were identified using electronic medical records from the Research Action for Health Network (2012–2018). Progression to moderate-to-severe and progression to severe hyperkalemia were defined as the first occurrences of a serum potassium measure > 5.5 and > 6.0 mEq/L, respectively. Kaplan–Meier analyses were conducted to estimate progression rates for all patients and by pre-specified patient subgroups. Hazard ratios (HR) of moderate-to-severe and severe hyperkalemia progression were estimated using Cox models.

Results

Of 35,369 patients with mild hyperkalemia, 16.9% and 8.7% progressed to moderate-to-severe and severe hyperkalemia, respectively. Rates of hyperkalemia progression elevated with the severity of chronic kidney disease (CKD). The highest progression rates were seen in patients with CKD stage 5 (stage 5 vs. no CKD: moderate-to-severe, 50.2% vs. 12.0%; severe, 31.3% vs. 3.9%; p < 0.001). Higher progression rates were also observed in patients with heart failure, hypertension, and type II diabetes compared with patients without those conditions (all p < 0.001). The most prominent risk factors were CKD stage 5 (HR of progression to moderate-to-severe hyperkalemia, 3.32 [95% CI 3.03–3.64]; severe, 4.08 [3.55–4.69]), CKD stage 4 (2.19 [1.97–2.43], 2.28 [1.92–2.71]), CKD stage 3 (1.57 [1.46–1.68], 1.65 [1.46–1.87]), type I diabetes (1.37 [1.18–1.61], 1.54 [1.23–1.93]), and serum potassium (1.12 [1.10–1.15], 1.13 [1.10–1.17] per 0.1 mEq/L increase) (all p values < 0.05).

Conclusion

Hyperkalemia progression rates increased significantly with CKD stage and were also higher among patients with higher baseline potassium level, heart failure, hypertension, and diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373(1):60–72.CrossRef Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373(1):60–72.CrossRef
2.
go back to reference Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–3.CrossRef Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–3.CrossRef
3.
go back to reference Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26(3):377–84.CrossRef Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26(3):377–84.CrossRef
4.
go back to reference Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–8.CrossRef Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–8.CrossRef
5.
go back to reference Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–48.CrossRef Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–48.CrossRef
6.
go back to reference Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009;339:b4114.CrossRef Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009;339:b4114.CrossRef
7.
go back to reference Faxén J, Xu H, Evans M, Jernberg T, Szummer K, Carrero J-J. Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome. Int J Cardiol. 2019;274:52–8.CrossRef Faxén J, Xu H, Evans M, Jernberg T, Szummer K, Carrero J-J. Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome. Int J Cardiol. 2019;274:52–8.CrossRef
8.
go back to reference Brueske B, Sidhu MS, Schulman-Marcus J, Kashani KB, Barsness GW, Jentzer JC. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc. 2019;8(7):e011814.CrossRef Brueske B, Sidhu MS, Schulman-Marcus J, Kashani KB, Barsness GW, Jentzer JC. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc. 2019;8(7):e011814.CrossRef
9.
go back to reference Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–93.CrossRef Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–93.CrossRef
10.
go back to reference Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, et al. Management of hyperkalemic patients in the inpatient setting by hyperkalemia severity. In: Presented at the 2019 Academy of Managed Care & Specialty Pharmacy Annual Meeting held March 25–28, 2019, San Diego, California. Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, et al. Management of hyperkalemic patients in the inpatient setting by hyperkalemia severity. In: Presented at the 2019 Academy of Managed Care & Specialty Pharmacy Annual Meeting held March 25–28, 2019, San Diego, California.
11.
go back to reference Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155–65.CrossRef Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155–65.CrossRef
12.
go back to reference Davis J, Israni R, Betts K, et al. Management of hyperkalemic patients in the emergency department setting. Boston: National Kidney Foundation; 2019. Davis J, Israni R, Betts K, et al. Management of hyperkalemic patients in the emergency department setting. Boston: National Kidney Foundation; 2019.
13.
go back to reference Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113(Pt A):585–91.CrossRef Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113(Pt A):585–91.CrossRef
14.
go back to reference Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2019;32(4):499–516.CrossRef Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2019;32(4):499–516.CrossRef
15.
go back to reference Weir MR. Current and future treatment options for managing hyperkalemia. Kidney Int Suppl. 2016;6(1):29–34.CrossRef Weir MR. Current and future treatment options for managing hyperkalemia. Kidney Int Suppl. 2016;6(1):29–34.CrossRef
16.
go back to reference Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int. 2016;89(3):546–54.CrossRef Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int. 2016;89(3):546–54.CrossRef
17.
go back to reference Mount DB. Treatment and prevention of hyperkalemia in adults. UpToDate. Waltham (MA): Wolters Kluwer; 2013. Mount DB. Treatment and prevention of hyperkalemia in adults. UpToDate. Waltham (MA): Wolters Kluwer; 2013.
18.
go back to reference Palmer BF, Clegg DJ. Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity. Mayo Clin Proc. 2016;91(4):496–508. Palmer BF, Clegg DJ. Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity. Mayo Clin Proc. 2016;91(4):496–508.
19.
go back to reference Burnier M. Should we eat more potassium to better control blood pressure in hypertension? Nephrol Dial Transplant. 2018;34(2):184–93.CrossRef Burnier M. Should we eat more potassium to better control blood pressure in hypertension? Nephrol Dial Transplant. 2018;34(2):184–93.CrossRef
20.
go back to reference Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis. 2005;45(6):978–93.CrossRef Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis. 2005;45(6):978–93.CrossRef
21.
go back to reference Magner PO, Robinson L, Halperin RM, Zettle R, Halperin ML. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis. 1988;11(3):220–4.CrossRef Magner PO, Robinson L, Halperin RM, Zettle R, Halperin ML. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis. 1988;11(3):220–4.CrossRef
22.
go back to reference Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study. J Am Heart Assoc. 2018;7(11):e008912.CrossRef Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study. J Am Heart Assoc. 2018;7(11):e008912.CrossRef
23.
go back to reference DeFronzo RA, Sherwin RS, Felig P, Bia M. Nonuremic diabetic hyperkalemia: possible role of insulin deficiency. Arch Intern Med. 1977;137(7):842–3.CrossRef DeFronzo RA, Sherwin RS, Felig P, Bia M. Nonuremic diabetic hyperkalemia: possible role of insulin deficiency. Arch Intern Med. 1977;137(7):842–3.CrossRef
24.
go back to reference Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6(4):272–80.CrossRef Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6(4):272–80.CrossRef
25.
go back to reference Yan T, Wang J, Li J, et al. Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents. BMC Infect Dis. 2019;19(1):550.CrossRef Yan T, Wang J, Li J, et al. Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents. BMC Infect Dis. 2019;19(1):550.CrossRef
26.
go back to reference Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008;4(4):387–99.CrossRef Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008;4(4):387–99.CrossRef
27.
go back to reference National Collaborating Centre for Chronic Conditions (UK). Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians; 2008. National Collaborating Centre for Chronic Conditions (UK). Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians; 2008.
28.
go back to reference Levey AS, Lau J, Uhlig K, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl. 1):11–3. Levey AS, Lau J, Uhlig K, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl. 1):11–3.
29.
go back to reference Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202.PubMedPubMedCentral Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202.PubMedPubMedCentral
30.
go back to reference Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012;2(6):e002011.CrossRef Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012;2(6):e002011.CrossRef
Metadata
Title
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
Authors
Rubeen Israni
Keith A. Betts
Fan Mu
Jill Davis
Jessie Wang
Deborah Anzalone
Gabriel I. Uwaifo
Harold Szerlip
Vivian Fonseca
Eric Wu
Publication date
01-11-2021
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 11/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-021-01925-1

Other articles of this Issue 11/2021

Advances in Therapy 11/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.